Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS (Tables)

v3.22.2.2
INTANGIBLE ASSETS (Tables)
9 Months Ended
Sep. 30, 2022
INTANGIBLE ASSETS [Abstract]  
Schedule of Intangible Assets

Intangible assets at September 30, 2022 and December 31, 2021 consist of the following:

   
September 30, 2022
   
December 31, 2021
 
           Accumulated                  Accumulated        
   
Cost
   
Amortization
   
Net
   
Cost
   
Amortization
   
Net
 
Trademark and other intangible rights related to Nabi-HB
 
$
4,100,046
   
$
3,123,845
   
$
976,201
   
$
4,100,046
   
$
2,684,554
   
$
1,415,492
 
Rights to intermediates
   
907,421
     
691,368
     
216,053
     
907,421
     
594,145
     
313,276
 
   
$
5,007,467
   
$
3,815,213
   
$
1,192,254
   
$
5,007,467
   
$
3,278,699
   
$
1,728,768
 
Intangible Asset Future Aggregate Amortization Expense

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.5 million for the nine months ended September 30, 2022 and 2021 and $0.2 million for the three months ended September 30, 2022 and 2021. Estimated future aggregate amortization expense is expected to be as follows:

Remainder of 2022
 
$
178,838
 
2023
   
715,352
 
2024
   
298,064